Products from BPS Bioscience require a minimum order value above 400€
Encompassing Amino Acids: 1-297
Application: Useful for animal immunization, ELISA, and PK assay.
Assay Conditions: Immobilized Human CD20 VLP at 5 μg/mL (100 μL/Well) on the plate.
Background: CD20 (also known as MS4A1) is a glycosylated phosphoprotein expressed on the cell surface of B cells. CD20 is a highly attractive target antigen for immunotherapy because it is highly expressed in more than 90% of patients with B-cell lymphoma. First approved in 1997, Rituximab (Rituxan) is a chimeric monoclonal antibody targeting CD20 and has been classified by the World Health Organization as an “Essential Medicine”. Since then, additional monoclonal antibodies against CD20 have been approved or are being tested in clinical trials for the treatment of multiple sclerosis (MS), chronic lymphocytic leukemia (CLL), follicular lymphoma, diffuse large B cell lymphoma (DLBCL), rheumatoid arthritis, non-Hodgkin’s lymphoma, systemic lupus erythematosus, and myalgic encephalomyelitis (chronic fatigue syndrome). More recently, anti-CD20-anti-CD19 bispecific CAR-T cells have been developed to address concerns over potential relapse in cancer patients.
Biological Activity: Dose response curve for Rituximab, hFc Tag with the EC50 of 33.5 ng/mL determined by ELISA.
Description: Human CD20 protein, full length encompassing amino acids 1-297(end). This construct is tag-free and was produced using VLP (virus-like particle) technology.
Format: Aqueous buffer solution.
Formulation: Supplied as a 0.22 μm filtered solution of PBS, pH 7.4.
Purity: ≥95% (determined by HPLC)
Storage Stability: Stored at -80°C for 1 year. It is stable at -20°C for 3 months after opening. It is recommended to freeze aliquots at -80°C forextended storage. Avoid repeated freeze-thaw cycles.
Target: CD20
Uniprot: P11836
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: BSL-1
English
Deutsch
